Schmith VD - Search Results

1

Prospective use of population pharmacokinetics/pharmacodynamics in the development of cisatracurium.

Schmith VD, Fiedler-Kelly J, Phillips L, Grasela TH Jr. Schmith VD, et al. Pharm Res. 1997 Jan;14(1):91-7. doi: 10.1023/a:1012015719694. Pharm Res. 1997. PMID: 9034227 Clinical Trial.

2

Population pharmacodynamics of doxacurium.

Schmith VD, Fiedler-Kelly J, Abou-Donia M, Huffman CS, Grasela TH Jr. Schmith VD, et al. Clin Pharmacol Ther. 1992 Nov;52(5):528-36. doi: 10.1038/clpt.1992.181. Clin Pharmacol Ther. 1992. PMID: 1424427 Clinical Trial.

3

Importance of the organ-independent elimination of cisatracurium.

Kisor DF, Schmith VD, Wargin WA, Lien CA, Ornstein E, Cook DR. Kisor DF, et al. Among authors: schmith vd. Anesth Analg. 1996 Nov;83(5):1065-71. doi: 10.1097/00000539-199611000-00029. Anesth Analg. 1996. PMID: 8895287

4

Dose proportionality of cisatracurium.

Schmith VD, Fiedler-Kelly J, Phillips L, Grasela TH Jr. Schmith VD, et al. J Clin Pharmacol. 1997 Jul;37(7):625-9. doi: 10.1002/j.1552-4604.1997.tb04345.x. J Clin Pharmacol. 1997. PMID: 9243356 Clinical Trial.

5

Clinical pharmacokinetics of cisatracurium besilate.

Kisor DF, Schmith VD. Kisor DF, et al. Among authors: schmith vd. Clin Pharmacokinet. 1999 Jan;36(1):27-40. doi: 10.2165/00003088-199936010-00003. Clin Pharmacokinet. 1999. PMID: 9989341 Review.

6

The influence of renal function on the pharmacokinetics and pharmacodynamics and simulated time course of doxacurium.

Fisher DM, Reynolds KS, Schmith VD, Hsu J, Sokoll MD, Lennon RL, Caldwell JE. Fisher DM, et al. Among authors: schmith vd. Anesth Analg. 1999 Sep;89(3):786-95. doi: 10.1097/00000539-199909000-00049. Anesth Analg. 1999. PMID: 10475326 Clinical Trial.

7

Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia.

Lien CA, Schmith VD, Belmont MR, Abalos A, Kisor DF, Savarese JJ. Lien CA, et al. Among authors: schmith vd. Anesthesiology. 1996 Feb;84(2):300-8. doi: 10.1097/00000542-199602000-00007. Anesthesiology. 1996. PMID: 8602660 Free article. Clinical Trial.

8

The effects of epoprostenol on drug disposition. I: A pilot study of the pharmacokinetics of digoxin with and without epoprostenol in patients with congestive heart failure.

Carlton LD, Patterson JH, Mattson CN, Schmith VD. Carlton LD, et al. Among authors: schmith vd. J Clin Pharmacol. 1996 Mar;36(3):247-56. doi: 10.1002/j.1552-4604.1996.tb04195.x. J Clin Pharmacol. 1996. PMID: 8690819 Clinical Trial.

9

The effects of epoprostenol on drug disposition. II: A pilot study of the pharmacokinetics of furosemide with and without epoprostenol in patients with congestive heart failure.

Carlton LD, Patterson JH, Mattson CN, Schmith VD. Carlton LD, et al. Among authors: schmith vd. J Clin Pharmacol. 1996 Mar;36(3):257-64. doi: 10.1002/j.1552-4604.1996.tb04196.x. J Clin Pharmacol. 1996. PMID: 8690820 Clinical Trial.

10

The pharmacokinetics and pharmacodynamics of GW395058, a peptide agonist of the thrombopoietin receptor, in the dog, a large-animal model of chemotherapy-induced thrombocytopenia.

Case BC, Hauck ML, Yeager RL, Simkins AH, de Serres M, Schmith VD, Dillberger JE, Page RL. Case BC, et al. Among authors: schmith vd. Stem Cells. 2000;18(5):360-5. doi: 10.1634/stemcells.18-5-360. Stem Cells. 2000. PMID: 11007920

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

44 results

Search Page